论文部分内容阅读
目的观察阿托伐他汀联合疏血通对难治性肾病的治疗作用。方法将患者随机分为对照组和治疗组。在常规应用激素等对症治疗的同时,治疗组加用阿托伐他汀10~20 mg/d,疏血通8 ml/d,平均治疗5周,观察两组治疗前后血浆凝血酶原时间(PT)、国际化标准值(INR)、纤维蛋白原(FIB)、凝血酶时间(TT)、部分凝血酶时间(APTT)、血浆D-二聚体(D-D)、血肌酐(Scr)、甘油三酯(TG)、总胆固醇(CHOL)、24 h尿蛋白定量(UAER)等各项指标的变化。结果治疗组治疗后TG、CHOL、D-D及APTT低于治疗前(P<0.05或P<0.01);治疗前后治疗组UAER及血肌酐下降较对照组明显(P<0.05或P<0.01)。结论阿托伐他汀联合疏血通能有效地改善难治性肾病的高凝状态,减少尿蛋白,延缓肾脏病变的进展。
Objective To observe the therapeutic effect of atorvastatin combined with Shuxuetong on refractory nephropathy. Methods Patients were randomly divided into control group and treatment group. In the routine application of hormones and other symptomatic treatment at the same time, the treatment group with atorvastatin 10 ~ 20 mg / d, shuxuetong 8 ml / d, the average treatment for 5 weeks, the two groups before and after treatment to observe the prothrombin time (PT ), INR, FIB, TT, APTT, DD, Scr, (TG), total cholesterol (CHOL), 24 h urinary protein (UAER) and other indicators of changes. Results The levels of TG, CHOL, D-D and APTT in the treatment group were lower than those before treatment (P <0.05 or P <0.01). The levels of UAER and serum creatinine in the treatment group were significantly lower than those in the control group before and after treatment (P <0.05 or P <0.01). Conclusion Atorvastatin combined with Shuxuetong can effectively improve the hypercoagulable state of refractory nephropathy, reduce urinary protein, delay the progression of renal disease.